activin A receptor type 2BGenealiases: ACTRIIB · ActR-IIB · HTX4
Q-omics provides the consensus-scored ACVR2B profile across patient tissues and cancer cell-line models. ACVR2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ACVR2B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ACVR2B RNA expression shows 22,278 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, HNSC, and LSCC as cancer lineages where ACVR2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACVR2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACVR2B survival associations across molecular data types. ACVR2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACVR2B RNA expression–survival associations across cancer types. High ACVR2B expression shows unfavorable associations in LIHC, but favorable associations in UCS, SCLC, KIRC, LGG and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ACVR2B RNA expression.
This table summarizes ACVR2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACVR2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACVR2B shows higher tumor expression in HNSC, COAD, BLCA, LUAD, LIHC and CHOL. The HNSC box plot shows higher ACVR2B RNA expression in tumor versus normal tissue (log2 FC = +0.447, t-test p < 0.001).
This table shows molecular features associated with ACVR2B in patient tissues and cancer cell lines. In patient samples, ACVR2B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACVR2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
